Supporting Information

Biomimetic Cytomembrane Nanovaccine Prevents Breast Cancer Development in the Long Term

Long Xiao‡[a], Yu Huang‡[b], Yuhe Yang‡[c], Zhiwei Miao‡[a], Jie Zhu[a], Mengdan Zhong[a], Chencheng Feng[a], Wenkai Tang[a], Jinhua Zhou*[b], Lihong Wang*[a], Xin Zhao*[c], Zhirong Wang*[a]

[a]Center Laboratory, Zhangjiagang Traditional Chinese Medicine Hospital Affiliated to Nanjing University of Chinese Medicine, Zhangjiagang, Jiangsu, 215600, China.

[b]Department of Obstetrics and Gynecology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China.

[c]Department of Biomedical Engineering, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China.

‡These authors contributed equally to this work.

Corresponding e-mail address: jsjhzh@126.com (J. Zhou); zjgzy001@njucm.edu.cn (L. Wang); xin.zhao@polyu.edu.hk (X. Zhao); zjgfy_spine_wzr@njucm.edu.cn (Z. Wang);

Supplementary Figures

Figure. S-1. Cell viability of a) BMDCs and b) 4T1 cells treated with cell culture medium (negative control, NC), cell culture medium with 1% Triton X-100 (positive control, PC), cell culture medium with 4T1 cancer cell membranes (CCM), cell culture medium with P@R837 (P@R837), and cell culture medium with CCMP@R837 (CCMP@R837). CCMP@R837 and P@R837 groups have the same amount of R837. c) CCMP@R837 uptake by BMDCs. The percentage of FITC positive BMDCs treated with FITC-labelled PLGA nanoparticles (F#P), FITC-labelled P@R837 nanoparticles (F# P@R837), and FITC-labelled CCMP@R837 nanoparticles (F# CCMP@R837) (n =3; *p < 0.05, ***p < 0.001).

**Figure S-2.** Body weight of BALB/c immunized with various formulations.

Figure S-3. Concentration of TNF-α in the serum of BALB/c mice immunized with various formulations. Blue color indicates saline, red for cancer cell membranes, green for P@R837 and purple for CCMP@R837 (n =3; *$p < 0.05$, ***$p < 0.001$).